Drug
Saxagliptin clinical trials
Also written Onglyza and BMS-477118.
- studies test it
- 94
- open now
- 1
- in phase 3
- 33
- first study started
- 2003
Keep track of what changes. Save the saxagliptin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Onglyza
- 61
Development codes
Studies by the year they started
94 studies that test it; most in 2012 (15)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 2 |
| 2006 | 5 |
| 2007 | 1 |
| 2008 | 7 |
| 2009 | 12 |
| 2010 | 6 |
| 2011 | 4 |
| 2012 | 15 |
| 2013 | 6 |
| 2014 | 13 |
| 2015 | 12 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 18
- Phase 2
- 5
- Phase 3
- 33
- Phase 4
- 32
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 60 · Other 34
AstraZeneca (56) · Shanghai Jiao Tong University School of Medicine (3) · The University of Texas Health Science Center at San Antonio (2) · Ram Weiss (2) · Phoenix VA Health Care System (1) · Cook County Health (1) · University of Pisa (1) · Second Xiangya Hospital of Central South University (1)
Often tested with
Tested in the same studies.
Metformin (17) · Dapagliflozin (15) · Sitagliptin (7) · Glimepiride (4) · Vildagliptin (3) · Cholecalciferol (1) · Acarbose (1) · Extended Release Metformin Hydrochloride (1)
Studies
Open first, then newest update. How each study uses saxagliptin is read from its arms, and is right about nine times in ten.
Testing it · 94
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)RecruitingNot applicableThe University of Texas Health Science Center at San AntonioNCT02969798Written as Saxagliptin
- To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus PatientsCompletedPhase 4AstraZenecaNCT04445714Written as dapagliflozin and saxagliptin
- Effects of Saxagliptin on Adipose Tissue Inflammation in HumansCompletedPhase 4Phoenix VA Health Care SystemNCT02285985Written as Saxagliptin
- Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years OldCompletedPhase 3AstraZenecaNCT03199053Written as Saxagliptin
- Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe HyperglycemiaCompletedPhase 4Cook County HealthNCT01267448Written as Saxagliptin + Metformin XR
- Effects of DPP-4 Inhibition on TriglyceridesSuspendedPhase 4Oregon Health and Science UniversityNCT01527747Written as Saxagliptin
- Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.CompletedPhase 2University of PisaNCT03714594Written as Saxagliptin 5mg
- Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart FailureCompletedPhase 4AstraZenecaNCT02917031Written as Saxagliptin
- Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune DiabetesCompletedPhase 4Second Xiangya Hospital of Central South UniversityNCT02407899Written as Saxagliptin
- Tubular Markers in Response to Saxagliptin TherapyCompletedPhase 4Beni-Suef UniversityNCT04521049Written as Saxagliptin 5mg
- A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin AloneCompletedPhase 3AstraZenecaNCT02419612Written as Saxagliptin
- Saxagliptin and Cardiac Structure and FunctionCompletedPhase 4Unity Health TorontoNCT02481479Written as Saxagliptin
- Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte InflammationTerminatedPhase 4Baylor College of MedicineNCT01548651Written as Saxagliptin
- Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy VolunteersStatus unknownNot applicableAin Shams UniversityNCT04170790Written as Saxagliptin 5mg
- DPP4inhibitors in Type 1 DiabetesCompletedPhase 3University of DundeeNCT01922817Written as Saxagliptin
- A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKDCompletedPhase 2/3AstraZenecaNCT02547935Written as Saxagliptin 2.5 mg
- ESR-15-11293 - Saxa/Dapa, Safety and Efficacy StudyCompletedNot applicableThe University of Texas Health Science Center at San AntonioNCT02613897Written as Saxagliptin
- Neuropeptide Y and Sympathovagal BalanceCompletedEarly Phase 1Eric GrouzmannNCT03933787Written as Saxagliptin 5mg
- Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With SulphonylureaCompletedPhase 4AstraZenecaNCT02471404Written as Saxagliptin
- Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM PatientsCompletedPhase 4George Washington UniversityNCT02024477Written as Saxagliptin
See all 94 studies that test saxagliptin →
Given in every arm · 9 — saxagliptin is usual care beside what is tested
- Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic ControlCompletedPhase 3University of BasrahNCT06107153Written as Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg
- Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/SaxagliptinTerminatedPhase 3AstraZenecaNCT03608358Written as Saxagliptin 5 mg
- Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 DiabetesCompletedPhase 2Nick Giannoukakis, PhDNCT02597101Written as saxagliptin
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on MetforminCompletedPhase 3AstraZenecaNCT02551874Written as Saxagliptin, Onglyza
- Effects of Antidiabetic Medications on the Postprandial State in PrediabetesCompletedPhase 4The University of Texas Health Science Center, HoustonNCT02104739Written as Saxagliptin
- A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 DiabetesCompletedPhase 4Uppsala UniversityNCT02765204Written as Saxagliptin
- Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 DiabetesCompletedPhase 3AstraZenecaNCT01646320Written as Saxagliptin
- Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 DiabetesStatus unknownPhase 4Fifth Affiliated Hospital, Sun Yat-Sen UniversityNCT02605772Written as Saxagliptin
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-AdministrationCompletedPhase 1AstraZenecaNCT01755494Written as Saxagliptin 5 mg
As the comparator · 4 — what is tested is compared with saxagliptin
- Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes MellitusTerminatedPhase 4Sabyasachi SenNCT03660683Written as Saxagliptin 5mg
- Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy SubjectsCompletedPhase 1AstraZenecaNCT03138356Written as 2.5 mg ONGLYZA® (saxagliptin) tablet
- Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose HomeostasisCompletedPhase 3Woman'sNCT02022007Written as Saxagliptin
- Incretin Effect on the Immunological PhenotypeCompletedPhase 2Medical University of GrazNCT01782261Written as Saxagliptin
Codes
What other systems call saxagliptin · ClinicalTrials.gg INT004805
- MeSH (NLM) C502994saxagliptinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9GB927LAJWSAXAGLIPTINConfirmed FDA, NLM, Wikidata
- RxNorm 857974One source FDA
- Wikidata Q27139483saxagliptin hydrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C75983SaxagliptinOne source FDA
- DrugBank DBSALT002375One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C502994 | saxagliptin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9GB927LAJW | SAXAGLIPTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 857974 | — | One source FDA |
| Wikidata | Q27139483 | saxagliptin hydrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C75983 | Saxagliptin | One source FDA |
| DrugBank | DBSALT002375 | — | One source Wikidata |
Also registered as saxagliptin anhydrous (UNII 8I7IO46IVQ · RxNorm 1546030) and saxagliptin hydrochloride (UNII Z8J84YIX6L · RxNorm 1043560).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.